Thus, DV-activated osteoclasts may contribute significantly to the clinical symptoms in DV-infected patients, and blockade of CLEC5A has the potential to alleviate DV-induced immunopathology and clinical symptoms in dengue patients. The gene discussed is CLEC5A; the disease is dengue disease.